bluebird bio, Inc.
TGFBeta SIGNAL CONVERTOR

Last updated:

Abstract:

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

Status:
Application
Type:

Utility

Filling date:

17 Nov 2017

Issue date:

21 Nov 2019